Pipeline progress Late stage summary Our pipeline remains extensive.
In total we have around 40 new molecular entities NMEs in phase II III clinical development.
A summary of pharmaceuticals and vaccines in phase III development is set out below.
A more comprehensive list of our medicines and vaccines in phases I to III of development is available on pages 225-228.
Therapeutic area Compound Indication Phase III Filed Approved Respiratory mepolizumab severe asthma also eosinophilic granulomatosis with polyangiitis Relvar Breo Ellipta COPD mortality outcomes vilanterol fluticasone furoate vilanterol COPD fluticasone furoate asthma Incruse Ellipta umeclidinium COPD also hyperhidrosis Anoro Ellipta umeclidinium vilanterol COPD Relvar Breo Ellipta asthma vilanterol fluticasone furoate Relvar Breo Ellipta COPD vilanterol fluticasone furoate Paediatric Vaccines MMR measles, mumps, rubella prophylaxis US Mosquirix Malaria RTS, S malaria prophylaxis Plasmodium falciparum Nimenrix MenACWY-TT Neisseria meningitis groups A, C, W & Y disease prophylaxis Other Vaccines Zoster Herpes Zoster prophylaxis Flu prepandemic pre-pandemic & pandemic influenza prophylaxis Flu vaccine seasonal influenza prophylaxis MAGE-A3 immunotherapeutic treatment of melanoma Antigen-Specific Cancer Immunotherapeutic MAGE-A3 immunotherapeutic treatment of non-small cell lung cancer HIV dolutegravir abacavir HIV infections fixed dose combination sulphate lamivudine Tivicay dolutegravir HIV infections Oncology Arzerra ofatumumab chronic lymphocytic leukaemia, use in relapsed patients Arzerra ofatumumab diffuse large B cell lymphoma relapsed patients Arzerra ofatumumab follicular lymphoma refractory & relapsed patients Mekinist trametinib metastatic melanoma, adjuvant therapy Tafinlar dabrafenib Tyverb Tykerb lapatinib breast cancer, neo-adjuvant & adjuvant therapy Votrient pazopanib renal cell cancer, adjuvant therapy Arzerra ofatumumab chronic lymphocytic leukaemia, first line therapy Votrient pazopanib ovarian cancer, maintenance therapy Mekinist trametinib metastatic melanoma Mekinist trametinib metastatic melanoma Tafinlar dabrafenib Revolade Promacta hepatitis C induced thrombocytopaenia eltrombopag Tafinlar dabrafenib metastatic melanoma Tyverb Tykerb lapatinib metastatic breast cancer, in combination with trastuzumab Cardiovascular & darapladib atherosclerosis also diabetic macular oedema Metabolic Eperzan albiglutide type 2 diabetes Immuno-inflammation Benlysta s. c. belimumab systemic lupus erythematosus Benlysta belimumab vasculitis sirukumab rheumatoid arthritis Rare diseases 2696273 adenosine deaminase severe combined immune deficiency ADA-SCID mepolizumab eosinophilic granulomatosis with polyangiitis also severe asthma Volibris ambrisentan chronic thromboembolic pulmonary hypertension Infectious diseases Relenza i. v. zanamivir influenza Dermatology Toctino alitretinoin chronic hand eczema Duac low dose acne vulgaris In-licence or other alliance relationship with third party The use of the brand name is not approved by any regulatory authorities GSK Annual Report 2013 43
